| VRT |
Report |
Adjusted EPS |
BEAT |
pred ~$1.50 vs. cons $1.439 |
MEDIUM |
| VRT |
Report |
Net sales |
BEAT |
pred ~$3.45B vs. cons $3.391B |
MEDIUM |
| VRT |
Report |
Adjusted operating margin |
BEAT |
pred ~21.8% vs. cons 21.46% |
MEDIUM |
| VRT |
Guide |
Adjusted EPS (Q3'26) |
BETTER |
guide ~$1.84 vs. cons $1.795 |
MEDIUM |
| VRT |
Guide |
Net sales (Q3'26) |
BETTER |
guide ~$3.80B vs. cons $3.718B |
MEDIUM |
| VRT |
Guide |
Adjusted EPS (FY26) |
BETTER |
guide ~$6.60 vs. cons $6.483 |
MEDIUM |
| VRT |
Guide |
Net sales (FY26) |
BETTER |
guide ~$14.10B vs. cons $13.887B |
MEDIUM |
| VRT |
Guide |
Demand / EMEA / H2 margin commentary (FY26) |
BETTER |
strong-orders, EMEA-recovery, H2-margin confirmation |
MEDIUM |
| VRT |
Return |
Day-1 residual (stock − beta × S&P 500) |
+4.0% |
— |
LOW |
| VRT |
Return |
5-day cumulative residual |
+5.0% (FOLLOW-THROUGH) |
FOLLOW-THROUGH — H2 revisions follow |
LOW |